What do German Molecular Tumor Boards recommend in patients with PIK3CA mutated tumors? - Launch and first results from the German TEAM-D Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D).
Journal
Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
received:
03
02
2024
accepted:
26
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
7
5
2024
Statut:
aheadofprint
Résumé
Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field. During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented. Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting. In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.
Sections du résumé
BACKGROUND AND RATIONALE
OBJECTIVE
Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field.
METHODS
METHODS
During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.
RESULTS
RESULTS
Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.
CONCLUSIONS
CONCLUSIONS
In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.
Identifiants
pubmed: 38714183
pii: 000539217
doi: 10.1159/000539217
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
S. Karger AG, Basel.